SPOTLIGHT -
Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.
Hundreds of children to receive free eyecare, glasses
ROP: Treating and preventing blindness in preterm babies
NovaSight introducing CureSight to U.S. market
Managing a changing landscape of IRD pediatric cases
New genetic mutation behind childhood glaucoma identified
Visual outcomes after secondary IOL implantation in aphakic children